Search Results - "Heath, E.I"

Impact of Prior Radiation Treatment on Sipuleucel-T Product Parameters in PROCEED Patients by Furay, A, Nordquist, L.T, Dakhil, S.R, Green, N.B, Heath, E.I, Tutrone, R.F, Vogelzang, N.J, Armstrong, A.J, Cooperberg, M.R, Tyler, R.C, Whitmore, J.B, Higano, C.S

Get full text

4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2 by Taplin, M.E, Chi, K.N, Chu, F, Cochran, J, Edenfield, W.J, Antonarakis, E.S, Emmenegger, U, Heath, E.I, Hussain, A, Njar, V.C, Koletsky, A, Lipsitz, D, Nordquist, L, Pili, R, Rettig, M, Sartor, O, Shore, N.D, Marrinucci, D, Mamlouk, K, Montgomery, B

Get full text

42 POSTER NPI-2358 (a novel vascular disrupting agent) Phase 1 dose escalation trial with an RP2D cohort by Mita, M, Spear, M.A, Yee, L.K, Papadopoulos, K.P, Heath, E.I, Pilat, M, Romero, O, Lloyd, G.K, Mita, A, LoRusso, P

Get full text

885P - Spatial-temporal change in quantitative total bone imaging (QTBI) and circulating tumour cells (CTCs) in metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) by Liu, G., Kyriakopoulos, C.E., Lang, J.M., Sperger, J.M., Singh, A., Heath, E.I., Perlman, S., Mayer, T., Modelska, K., Porcari, A., Duggan, W., Jeraj, R.

“…We report secondary and exploratory analysis with 18F-NaF PET/CT and CTCs to determine how tumour burden and RNA expression of androgen receptor (AR) splice…”
Get full text

Spatial-temporal change in quantitative total bone imaging (QTBI) and circulating tumour cells (CTCs) in metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) by Liu, G., Kyriakopoulos, C.E., Lang, J.M., Sperger, J.M., Singh, A., Heath, E.I., Perlman, S., Mayer, T., Modelska, K., Porcari, A., Duggan, W., Jeraj, R.

Get full text

Randomized trial of androgen deprivation therapy (ADT) + enzalutamide (Arm A) versus ADT + bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC) by Vaishampayan, U.N., Heilbrun, L., Monk, P., Sonpavde, G., Tejwani, S., Heath, E.I., Fontana, J., Chinni, S.

Get full text

Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel by Cheng, H H, Gulati, R, Azad, A, Nadal, R, Twardowski, P, Vaishampayan, U N, Agarwal, N, Heath, E I, Pal, S K, Rehman, H-t, Leiter, A, Batten, J A, Montgomery, R B, Galsky, M D, Antonarakis, E S, Chi, K N, Yu, E Y

“…Background: Enzalutamide and abiraterone are new androgen-axis disrupting treatments for metastatic castration-resistant prostate cancer (mCRPC). We examined…”
Get full text

EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy by Rosenberg, J.E., Balar, A., O’Donnell, P.H., Heath, E.I., Hahn, N.M., Cavazos, N.M., Melhem-Bertrandt, A., Petrylak, D.P.

Get full text

Synthetic DNA immunotherapy in biochemically relapsed prostate cancer by Shore, N., Heath, E.I., Nordquist, L.T., Cheng, H., Bhatt, K., Morrow, M., McMullan, T., Kraynyak, K., Lee, J., Sacchetta, B., Liu, L., Rosencranz, S., Tagawa, S.T., Appleman, L.J., Tutrone, R., Garcia, J., Whang, Y., Kelly, W., Csiki, I., Bagarazzi, M.L.

Get full text

AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) by de Bono, J.S., Hansen, A., Choudhury, A.D., Cook, N., Heath, E.I., Higano, C., Linch, M., Martin-Liberal, J., Rathkopf, D.E., Wisinski, K.B., Barry, S., de Bruin, E., Brugger, W., Colebrook, S., Klinowska, T., Moschetta, M., Mortimer, P.G.S., Siu, L.L., Shapiro, G.

Get full text

P114 Safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Phase 2 results from a phase 1/2 study by Petrylak, D, Gandhi, J, Clark, W.R, Heath, E.I, Lin, J, Oh, W.K, Agus, D.B, Carthon, B, Moran, S, Mortimer, P, Liu, G

Get full text

Phase 2 Results from a Phase 1/2 Study of Tak-700 (ORTERONEL), An Oral, Investigational, Nonsteroidal 17,20-Lyase Inhibitor, with Docetaxel and Prednisone (DP) in Metastatic Castration-Resistant Prostate Cancer (MCRPC) by Petrylak, D.P., Gandhi, J.G., Clark, W.R., Heath, E.I., Lin, J., Oh, W.K., Agus, D.B., Carthon, B., Moran, S., Liu, G.

Get full text

757OGALETERONE IN 4 PATIENT POPULATIONS OF MEN WITH CRPC: RESULTS FROM ARMOR2 by Taplin, M., Chi, K.N., Chu, F., Cochran, J., Edenfield, W.J., Eisenberger, M., Emmenegger, U., Heath, E.I., Hussain, A., Koletsky, A., Lipsitz, D., Nordquist, L., Pili, R., Rettig, M., Sartor, O., Shore, N.D., Dhillon, R., Roberts, J., Montgomery, B.

“…Abstract Aim: Galeterone is an oral small molecule that disrupts androgen receptor (AR) signaling via multi-targeted mechanisms of action (MOA): (1) selective…”
Get full text

Galeterone in 4 Patient Populations of Men with Crpc: Results from Armor2 by Taplin, M., Chi, K.N., Chu, F., Cochran, J., Edenfield, W.J., Eisenberger, M., Emmenegger, U., Heath, E.I., Hussain, A., Koletsky, A., Lipsitz, D., Nordquist, L., Pili, R., Rettig, M., Sartor, O., Shore, N.D., Dhillon, R., Roberts, J., Montgomery, B.

Get full text

Galgenprostucel-L/Litgenprostucel-L by Al-Kadhimi, Z., Heath, E.I.

Get full text

Galgenprostucel-L/Litgenprostucel-L by Al-Kadhimi, Z., Heath, E.I.

Get full text

A novel computerized approach to enhancing lung tumor detection in whole-body PET images by Hao Ying, Fule Zhou, Shields, A.F., Muzik, O., Dafang Wu, Heath, E.I.

“…Positron emission tomography (PET) is complimentary to other imaging modalities such as CT and MRI and provides a unique and effective means for detecting…”
Get full text